Ivabradine may be associated with risks of bradycardia, atrial fibrillation, and other cardiovascular risks. It should now only be started if the resting heart rate is at least 70 beats per minute, and should not be prescribed with other medicines that cause bradycardia. Patients should be monitored regularly for atrial fibrillation and treatment stopped if there is only limited symptom improvement after 3 months.